- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00036452
A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
While many factors contribute to the success or failure of antiretroviral therapy for HIV, among the most important are factors that influence adherence to a treatment regimen, such as duration of therapy, dosing frequency, pill burden, side effects, and patient behaviors. Inconsistent adherence or nonadherence to antiretroviral therapy can result in suboptimal drug exposure. Suboptimal drug exposure can, in turn, impact short- and long-term patient outcomes by increasing the likelihood of drug resistant HIV mutants and subsequent virologic and clinical failure. It is therefore essential to design treatment regimens that promote long-term adherence to potent antiretroviral therapy. This study will evaluate the relative contribution of reduced-frequency dosing and directly observed therapy on the magnitude and durability of virologic suppression in patients treated with potent antiretroviral therapy.
Patients will be randomly assigned to one of three study arms. Arms A, B, and C receive the same daily dosage of lopinavir/ritonavir (LPV/r), emtricitabine (FTC), and stavudine extended release (d4T XR) or tenofovir DF (TDF). In Arm A, drugs are self-administered for 48 weeks; LPV/r is taken twice daily and FTC and d4T XR or TDF once daily. In Arm B, all drugs are self-administered once daily for 48 weeks. In Arm C, drugs are taken once a day under directly observed therapy during Weeks 0-24, and then by self-administration during Weeks 25-48. Adherence to the regimen is measured using an electronic drug monitoring system. Viral load, CD4 and CD8 T cell responses, population pharmacokinetics, and quality of life indicators are measured throughout the study. The tolerability and safety of the treatment regimens are also monitored.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
San Juan, Puerto Rico, 00936-5067
- Puerto Rico-AIDS CRS
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90033-1079
- USC CRS
-
Sacramento, California, Verenigde Staten
- Univ. of California Davis Med. Ctr., ACTU
-
San Diego, California, Verenigde Staten, 92103
- Ucsd, Avrc Crs
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80262
- University of Colorado Hospital CRS
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- Univ. of Miami AIDS CRS
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96816-2396
- Univ. of Hawaii at Manoa, Leahi Hosp.
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202-5250
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins Adult AIDS CRS
-
Baltimore, Maryland, Verenigde Staten, 21201
- IHV Baltimore Treatment CRS
-
-
Massachusetts
-
Fall River, Massachusetts, Verenigde Staten
- SSTAR, Family Healthcare Ctr.
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455-0392
- University of Minnesota, ACTU
-
-
New York
-
New York, New York, Verenigde Staten, 10003
- Beth Israel Med. Ctr., ACTU
-
New York, New York, Verenigde Staten, 10016
- NY Univ. HIV/AIDS CRS
-
Rochester, New York, Verenigde Staten, 14215
- Univ. of Rochester ACTG CRS
-
Rochester, New York, Verenigde Staten, 14642-0001
- AIDS Care CRS
-
Rochester, New York, Verenigde Staten, 14642-0001
- McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27514
- Unc Aids Crs
-
Greensboro, North Carolina, Verenigde Staten, 27401-1004
- Regional Center for Infectious Disease, Wendover Medical Center CRS
-
Raleigh, North Carolina, Verenigde Staten
- Wake County Health and Human Services CRS
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45267-0405
- Univ. of Cincinnati CRS
-
Cleveland, Ohio, Verenigde Staten, 44109-1998
- MetroHealth CRS
-
Columbus, Ohio, Verenigde Staten
- The Ohio State Univ. AIDS CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213-2582
- Pitt CRS
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02906
- The Miriam Hosp. ACTG CRS
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Vanderbilt Therapeutics CRS
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- University of Washington AIDS CRS
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Zuid-Afrika
- Wits HIV CRS
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria
- HIV infection
- Age 13 years or older and have written consent of guardian if under 18
- Weigh at least 88 pounds
- Viral load of 2000 copies/ml or more within 90 days before study entry
- Have not taken anti-HIV drugs for more than 7 days
- Agree to use acceptable methods of contraception during the study and for 1 month after stopping the study drugs
Exclusion Criteria
- Pregnant or breastfeeding
- In jail
- Sensitive or allergic to any part of the study drugs
- Treated with acute systemic therapy for a serious infection or other serious medical illness within 7 days prior to study entry, unless the participant has completed 7 days of therapy and is clinically stable
- Recent serious illness, including pancreatitis or peripheral neuropathy
- Alcohol or illicit drug abuse
- Taken any of the following within 14 days before study entry: investigational drugs, anti-HIV vaccines, drugs that may cause pancreatitis or peripheral neuropathy, or drugs that are associated with CYP3A
- Treated for cancer (not including minimal Kaposi's sarcoma) within 30 days before study entry
- History of mental illness that might interfere with the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Donna Mildvan, MD, Beth Israel Medical Center
- Studie stoel: Charles Flexner, MD, Johns Hopkins University Hospital
Publicaties en nuttige links
Algemene publicaties
- Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21-30. doi: 10.7326/0003-4819-133-1-200007040-00004. Erratum In: Ann Intern Med 2002 Feb 5;136(3):253.
- Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001 May 15;134(10):968-77. doi: 10.7326/0003-4819-134-10-200105150-00011. Erratum In: Ann Intern Med 2002 Jan 15;136(2):175.
- Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet. 2000 Apr 15;355(9212):1345-50. doi: 10.1016/S0140-6736(00)02124-3. Erratum In: Lancet 2000 Jul 29;356(9227):434.
- Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001 Jun 1;110(8):664-6. doi: 10.1016/s0002-9343(01)00729-x. No abstract available.
- Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T, Graham NM, Gao H, Rosenzweig JR, McClernon DR, Pittman G, Hessenthaler SM, Hernandez JE; NZTA4007 Study Team. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002 Feb 15;34(4):511-8. doi: 10.1086/338400. Epub 2002 Jan 4.
- Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D; AIDS Clinical Trials Group A5073 Study Team. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med. 2009 Jul 13;169(13):1224-32. doi: 10.1001/archinternmed.2009.172.
- Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D; ACTG A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 1;50(7):1041-52. doi: 10.1086/651118.
Studie record data
Bestudeer belangrijke data
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- RNA-virusinfecties
- Virusziekten
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- Ziekten van het immuunsysteem
- HIV-infecties
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Reverse Transcriptase-remmers
- Nucleïnezuursyntheseremmers
- Enzymremmers
- Anti-hiv-middelen
- Antiretrovirale middelen
- Antimetabolieten
- Proteaseremmers
- Cytochroom P-450 CYP3A-remmers
- Cytochroom P-450 enzymremmers
- HIV-proteaseremmers
- Virale proteaseremmers
- Tenofovir
- Emtricitabine
- Ritonavir
- Lopinavir
- Stavudine
Andere studie-ID-nummers
- A5073
- 10073 (Register-ID: DAIDS ES)
- ACTG A5073
- AACTG A5073
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .